GLP-1 medications and your heart and kidneys: what 2026 research shows

• Landmark randomized controlled trials — LEADER, SUSTAIN-6, and SOUL — established that semaglutide and liraglutide reduce major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease
• A 2026 trial emulation published in Nature Medicine found that semaglutide showed approximately 20% reduction in MACE, 18% reduction in heart failure events, and 19% reduction in major kidney events compared to sitagliptin in real-world populations
• Tirzepatide showed similar cardiovascular benefits to semaglutide in the same 2026 analysis
• Most of the strongest evidence comes from patients with type 2 diabetes; evidence in people with obesity but without T2D is more limited
• These findings do not mean GLP-1s are approved to treat heart disease or kidney disease in all patients — they describe observed outcomes in specific trial populations

The cardiovascular benefit case for GLP-1 medications was built through rigorous randomized controlled trials (RCTs):

LEADER trial (2016): Liraglutide reduced the risk of MACE (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) by 13% compared to placebo in adults with type 2 diabetes and high cardiovascular risk.

SUSTAIN-6 trial (2016): Subcutaneous semaglutide reduced MACE by 26% compared to placebo in adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk.

SOUL trial (2024): Oral semaglutide demonstrated a 14% reduction in MACE versus placebo in adults with type 2 diabetes and established cardiovascular disease — confirming that the cardiovascular benefit extends to the oral formulation.

All three trials enrolled patients with type 2 diabetes — an important caveat when considering whether findings apply to people using GLP-1s primarily for obesity without diabetes.

A 2026 study published in Nature Medicine (Xu et al., nature.com/articles/s41591-026-04274-0) used a trial emulation approach — a methodology that applies RCT principles to real-world data — to compare outcomes among patients prescribed semaglutide, tirzepatide, or sitagliptin (an older diabetes medication) in a large real-world population.

Key findings from the Nature Medicine trial emulation:

• Semaglutide: Approximately 20% reduction in MACE vs sitagliptin
• Heart failure events: Approximately 18% reduction with semaglutide
• Major kidney events: Approximately 19% reduction with semaglutide
• Tirzepatide: Showed similar cardiovascular and kidney benefits to semaglutide in the same analysis

The Nature Medicine paper described these as "clinically significant" benefits and suggested that GLP-1 medications may provide cardiovascular and kidney protection through mechanisms beyond weight reduction alone — including reductions in inflammation, improvements in insulin sensitivity, and direct effects on cardiac and renal tissue.

Kidney protection has emerged as a meaningful area of GLP-1 research. The SELECT trial (semaglutide in obesity without T2D) included kidney outcomes as secondary endpoints, and its data showed kidney benefits even in patients without diabetes — one of the few datasets extending kidney protection evidence beyond the T2D population.

A 2026 review of real-world GLP-1 use across the spectrum of chronic kidney disease (CKD), summarized by the American Journal of Kidney Diseases Blog, found consistent signals for reduced kidney disease progression in GLP-1 users across multiple real-world datasets. However, the populations varied, and confounding factors — who gets prescribed GLP-1s, what else they're treated with — limit causal conclusions from observational data.

This is arguably the most important thing to understand when evaluating GLP-1 cardiovascular and kidney research:

• RCT evidence (LEADER, SUSTAIN-6, SOUL): All in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk. These patients have the strongest evidence base.

• Real-world trial emulation (Nature Medicine 2026): Also primarily in diabetes populations or high-risk patients, though the methodology attempts to approximate RCT conditions in observational data.

• Obesity without T2D: Evidence here is more limited. SELECT showed MACE reduction for semaglutide in people with obesity and cardiovascular disease but without T2D — an important extension, but not yet replicated across multiple large trials.

• CKD without T2D: Emerging data, but smaller population-level evidence.

Conclusions drawn from T2D trial populations do not automatically apply to all GLP-1 users. Your specific situation — diabetes status, kidney function, cardiovascular history — shapes how relevant this evidence is to you.

• Whether cardiovascular and kidney benefits observed in T2D populations are equally robust in people with obesity but no diabetes across all GLP-1 agents
• The specific mechanisms explaining benefits beyond weight loss (inflammation reduction, direct cardiac effects, hemodynamic changes) remain under active investigation
• Whether benefits extend to people with advanced CKD (stages 4–5), who were often excluded from major trials
• Long-term (10+ year) cardiovascular and kidney outcomes for people starting GLP-1s early in life or maintaining treatment indefinitely

• Given my cardiovascular history and diabetes status, does the evidence suggest I'm likely to benefit from cardiovascular or kidney protection beyond weight loss?
• Am I in a population where the RCT evidence is strongest, or am I extrapolating from populations that don't closely match my situation?
• Should my cardiologist or nephrologist be involved in decisions about my GLP-1 treatment, given these potential benefits?
• How should we monitor my kidney function and cardiovascular markers while I'm on this medication?

• eGFR (estimated glomerular filtration rate) and urine albumin-to-creatinine ratio at regular intervals if you have kidney disease
• Blood pressure and lipid panels at follow-up visits
• Any changes in exercise tolerance or symptoms that could signal cardiac changes
• HbA1c if you have type 2 diabetes

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional — including your cardiologist or nephrologist if relevant — before starting, stopping, or changing any treatment.

Sources

• Nature Medicine 2026 — Xu et al. (GLP-1 cardiorenal trial emulation)
• PMC cardiorenal review
• AJKD Blog — Real-world GLP-1 evidence across CKD spectrum
• LEADER trial — PubMed PMID 27295427
• SUSTAIN-6 trial — PubMed PMID 28095528